Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Financing Activities (2021 - 2025)

ARS Pharmaceuticals' Cash from Financing Activities history spans 5 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 98.41% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $104.6 million, up 44.47%, while the annual FY2025 figure was $104.6 million, 44.47% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $1.1 million at ARS Pharmaceuticals, down from $100.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $193.8 million in Q4 2022 and bottomed at -$1.6 million in Q3 2022.
  • The 5-year median for Cash from Financing Activities is $823000.0 (2023), against an average of $21.4 million.
  • The largest annual shift saw Cash from Financing Activities plummeted 1151.35% in 2022 before it skyrocketed 14612.5% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $52.8 million in 2021, then surged by 266.95% to $193.8 million in 2022, then tumbled by 99.07% to $1.8 million in 2023, then surged by 3828.86% to $70.9 million in 2024, then crashed by 98.41% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Cash from Financing Activities are $1.1 million (Q4 2025), $100.0 million (Q3 2025), and $2.7 million (Q2 2025).